Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
Royalty Pharma announced that Novartis' Phase 3 HORIZON trial for pelacarsen failed to meet its primary endpoint of reducing cardiovascular events in patients with elevated Lp(a). Despite the setback, Royalty Pharma expects to recoup its total $500 million investment and earn a modest positive return due to its protective deal structure that prioritized stable Spinraza royalties. The company reiterates its 2030 Portfolio Receipts target of $4.7 billion or more.